What is Mag07 (ozonated magnesium oxide supplement) and is it safe for treating constipation?

Mag07 for Constipation: What It Is and Safety Profile

Mag07 is an ozonated magnesium oxide supplement marketed for constipation, and while standard magnesium oxide is conditionally recommended by major gastroenterology guidelines for chronic constipation, it is generally safe but requires careful attention to kidney function and dosing—particularly avoiding use in patients with significant renal impairment (creatinine clearance <20 mg/dL or eGFR <30 mL/min/1.73m²).

What is Mag07?

Mag07 is a proprietary formulation of magnesium oxide that has been "ozonated" (combined with oxygen). The active ingredient is fundamentally magnesium oxide (MgO), which functions as an osmotic laxative. The ozonation process is a marketing feature, but the core therapeutic mechanism remains the same as standard magnesium oxide—creating an osmotic gradient in the intestinal lumen that draws water into the bowel, softening stool and promoting bowel movements 1, 2.

Evidence-Based Recommendations for Magnesium Oxide

Efficacy

The 2023 AGA-ACG Clinical Practice Guideline conditionally recommends magnesium oxide for chronic idiopathic constipation, though the certainty of evidence is very low 1. The guideline notes:

• MgO increases spontaneous bowel movements and complete spontaneous bowel movements per week compared to placebo
• Responder rates are significantly higher with MgO (RR 3.93,95% CI 2.04–7.56), meaning 499 more participants per 1,000 might respond to treatment 1
• Quality of life improves as measured by PAC-QOL scores
• Stool consistency improves based on Bristol Stool Form Scale 1

Recent dietary guidelines for constipation management also support magnesium oxide use, with multiple recommendation statements based on RCT evidence 3.

Safety Considerations: Critical Warnings

Absolute Contraindications

Avoid magnesium oxide entirely in patients with:

• Creatinine clearance <20 mg/dL 1
• eGFR <30 mL/min/1.73m² (equivalent contraindication from renal dosing principles)
• Severe renal impairment of any kind 1

High-Risk Populations Requiring Monitoring

The evidence reveals concerning safety signals in specific populations:

Elderly patients with renal dysfunction are at substantial risk for hypermagnesemia 4, 5. A case series documented four elderly patients (all >65 years) who developed symptomatic hypermagnesemia from MgO, with one fatality 4. Key risk factors include:

• Chronic kidney disease (CKD) Grade 4 is strongly associated with hypermagnesemia (p=0.014) 5
• Dosages >1,000 mg/day significantly increase risk (p=0.004) 5
• Concomitant use of stimulant laxatives increases serum magnesium levels (p=0.035) 5

In a cross-sectional study of 193 patients taking daily MgO:

• 16.6% had high serum magnesium (≥2.5 mg/dL)
• 5.2% had frank hypermagnesemia (≥3.0 mg/dL) 5

Monitoring Recommendations

For high-risk patients (elderly, any degree of renal impairment, doses >1,000 mg/day):

• Check baseline serum magnesium and creatinine before starting
• Recheck serum magnesium after initial prescription or dose increases 4
• Monitor for symptoms of hypermagnesemia: muscle weakness, hypotension, bradycardia, altered mental status

Practical Dosing Algorithm

Starting Approach

1. First-line for mild constipation: Start with 500 mg daily 1

   • The guideline explicitly recommends "starting at a lower dose" than the 1,500 mg/day used in RCTs
   • Lower doses (500-1,000 mg/day) are commonly used in clinical practice and appear effective 1, 6

2. Titration: Increase by 500 mg weekly based on response, up to maximum 1,500-2,000 mg/day 1

3. Dosing frequency: Can be given once daily or divided doses

   • Evidence suggests reducing frequency (e.g., three times daily to twice daily) while maintaining total daily dose does not reduce efficacy 6

Duration of Use

• RCTs evaluated 4 weeks of treatment, but longer-term use is probably appropriate 1
• No significant tolerance or tachyphylaxis has been documented
• Diarrhea rates are similar to placebo in trials 1

Comparison to Other Laxatives

Magnesium oxide is less effective than:

• Polyethylene glycol (PEG): Strongly recommended with moderate certainty evidence 1
• Elobixibat: Superior for improving rectal sensation and colonic transit time (87% vs 37% shift from slow to normal transit) 7

Magnesium oxide is comparable or superior to:

• Bulk laxatives in elderly patients (more frequent bowel movements, better stool consistency) 8
• Lactulose (though lactulose has more bloating/flatulence) 1

Common Pitfalls to Avoid

1. Using in unrecognized renal impairment: Always check baseline creatinine/eGFR
2. Excessive dosing: Start low (500 mg), not at RCT doses (1,500 mg)
3. Ignoring drug interactions: Concomitant stimulant laxatives increase magnesium absorption 5
4. Assuming "natural" means safe: Magnesium toxicity can be fatal 4
5. Not monitoring high-risk patients: Elderly and CKD patients need serum magnesium checks

Advantages of Magnesium Oxide

• Low cost and over-the-counter availability 1
• Generally well-tolerated with minimal GI side effects
• No significant diarrhea increase compared to placebo 1
• Improves quality of life beyond just bowel frequency 1
• Flexible dosing (can reduce frequency without losing efficacy) 6

Bottom Line for Mag07 Specifically

While Mag07 contains magnesium oxide as its active ingredient and should theoretically work similarly to standard MgO, there are no published RCTs specifically evaluating the "ozonated" formulation. The evidence base supporting magnesium oxide for constipation applies to standard pharmaceutical-grade magnesium oxide 1. The ozonation process is not mentioned in any clinical guidelines or research literature, and its clinical relevance is unproven.

Practical recommendation: Standard magnesium oxide (generic, inexpensive) is preferable to proprietary formulations like Mag07 given the established evidence base, lower cost, and known safety profile when used appropriately.